|
|
|
|
|
| Study on Hsp90 Expression in Different Tissues and Its Antibody in Serum of Chickens Infected with Marek’s Diseases |
| LI Yu-bao, LI Juan, WANG Zhi-liang , LIU Si-dang |
1、School of Agriculture, Liaocheng University, Liaocheng 252059, P.R.China
2、School of Veterinary Medicine, Shandong Agricultural University, Tai’an 271018, P.R.China
3、China Animal Health and Epidemiology Center, Qingdao 266032, P.R.China |
|
|
|
摘要 To investigate the dynamic change of heat shock protein 90 (Hsp90) in the genesis and development of tumor, we successfully established tumor animal model using Marek’s disease and then determined the location of Hsp90 in the tumor tissue using immunohistochemistry method, the antibody titer level of Hsp90 in the serum and the expression level in the tissue using enzymelinked immunosorbent assay (ELISA) method. Our result showed that Hsp90 location in the tumor tissue was significantly associated with the tumor cell and most in the cytoplasm of the tumor cell, and Hsp90 expression level in the tissue and the antibody titer level in the serum was most significantly increased with the development of tumor. This is the first report to show the presence of Hsp90 in tumor tissues induced by the Marek’s disease, with its expression correlated to the tumoral grading. These data may also be valuable for developing new molecular anti-cancer therapies.
Abstract To investigate the dynamic change of heat shock protein 90 (Hsp90) in the genesis and development of tumor, we successfully established tumor animal model using Marek’s disease and then determined the location of Hsp90 in the tumor tissue using immunohistochemistry method, the antibody titer level of Hsp90 in the serum and the expression level in the tissue using enzymelinked immunosorbent assay (ELISA) method. Our result showed that Hsp90 location in the tumor tissue was significantly associated with the tumor cell and most in the cytoplasm of the tumor cell, and Hsp90 expression level in the tissue and the antibody titer level in the serum was most significantly increased with the development of tumor. This is the first report to show the presence of Hsp90 in tumor tissues induced by the Marek’s disease, with its expression correlated to the tumoral grading. These data may also be valuable for developing new molecular anti-cancer therapies.
|
|
Received: 21 February 2013
Accepted:
|
| Fund: This work was supported by the National Natural Science Foundation of China (31101787) and the Natural Science Foundation of Shandong Province, China (ZR2010CM035). |
|
Corresponding Authors:
WANG Zhi-liang, Tel/Fax: +86-532-87839188, E-mail: zlwang111@163.com; LIU Si-dang, Tel/Fax: +86-538-8249526, E-mail: liusidang@126.com
|
| About author: LI Yu-bao, E-mail: liyubao@lcu.edu.cn; LI Juan, E-mail: li198820062011@163.com |
Cite this article:
LI Yu-bao, LI Juan, WANG Zhi-liang , LIU Si-dang.
2014.
Study on Hsp90 Expression in Different Tissues and Its Antibody in Serum of Chickens Infected with Marek’s Diseases. Journal of Integrative Agriculture, 13(6): 1355-1362.
|
| An W G, Schulte T W, Neckers L M. 2000. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth & Differentiation, 11, 355-360 Bagatell R, Whitesell L. 2004. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Molecular Cancer Therapeuticsr, 3, 1021-1030 Bao E D, Sultan K R, Nowak B, Hartung J. 2008. Expression and distribution of heat shock proteins in the heart of transported pigs. Cell Stress Chaperones, 13, 459-66 Basso A D, Solit D B, Munster P N, Rosen N. 2002. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21, 1159-1166 Blagosklonny M V, Toretsky J, Neckers L. 1995. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11, 933-939 Calnek B W, Witter R L. 1986. Marek’s disease-a model for herpesvirus oncology. Critical Reviews in Microbiology, 12, 293-320 Cho K O, Ohashi K, Onuma M. 1999. Electron microscopic and immunohistochemical localization of Marek’s disease (MD) herpesvirus particles in MD skin lymphomas. Veterinary Pathology Online, 36, 314-320 Cid C, Alvarez-Cermeno J C, Camafeita E, Salinas M, Alcazar A. 2004. Antibodies reactive to heat shock protein 90 induce oligodendrocyte precursor cell death in culture implications for demyelination in multiple sclerosis. The FASE Journal, 18, 409-411 Conroy S E, Gibson S L, Brunstrom G, Isenberg D, Luqmani Y, Latchman D S. 1995. Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients. Lancet, 345, 126. Conroy S E, Latchman D S. 1996. Do heat shock proteins have a role in breast cancer? British Journal of Cancer, 74, 717-721 Conroy S E, Sasieni P D, Fentiman I, Latchman D S. 1998. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. European Journal of Cancer, 34, 942-943 Conroy S E, Tucker L, Latchman D S, Isenberg D A. 1996. Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Clinical and Experimental Rheumatology, 14, 99-104 Donnelly A, Blagg B S. 2008. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry, 15, 2702-2717 Ferrarini M, Heltai S, Zocchi M R, Rugarli C. 1992. unusual expression and localization of heat-shock proteins inhuman tumor cells. International Journal of Cancer, 51, 613-619 Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, Amicis F D, Fuqua S A W, Catalano S, Andò S. 2013. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Molecular Oncology, 7, 379-397 Gress T M, Müller-Pillasch F, Weber C, Lerch M M, Friess H, Büchler M, Beger H G, Adler G, 1994. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Research, 54, 547-552 Hartson S D, Matts R L. 1994. Association of Hsp90 with cellular src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry, 33, 8912-8921 Hertlein E, Wagner A J, Jones J, Lin T S, Maddocks K J, Towns W H, Goettl V M, Zhang X, Jarjoura D, Raymond C A, West D A, Croce C M, Byrd J C, Johnson A J. 2010. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: Clinical implications of HSP90 inhibition. Blood, 116, 45-53 Hrycaj P, Wurm K, Mennet P, Muller W. 1995. Antibodies to heat shock proteins in patients with pulmonary sarcoidosis. Sarcoidosis, 12, 124-130 Kaiser P, Underwood G, Davison F. 2003. Differential cytokine responses following Marek’s disease virus infection of chickens differing in resistance to Marek’s disease. Journal of Virolog, 77, 762-768 Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M F, Fritz L C, Burrows F J. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 425, 407-410 Lang S A, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke M H, Dietmaier W, Bolder U, Schlitt H J, Geissler E K, Stoeltzing O. 2007. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Molecular Cancer Therapeutics, 6, 1123-1132 Lei L, Bao E D. 2008. Hsp90 expression in acute heat-stressed broilers and heat stress damage. Scientia Agricultura Sinica, 41, 3816-3821. (in Chinese) Li Y B, Pei L Y, Bao E D, Wang Z L, Zhao R Q. 2008. Relationship between distribution, transcription level of HSPs mRNA and immunity tissue pathological lesion of transport stressed pigs. Scientia Agricultura Sinica, 41, 1832-1837 (in Chinese) Li Y B, Sun P M, Wang Z L, Bao E D. 2005. Relationship between pathological lesion and distribution of HSP27 in transport stressed pigs. Journal of Nanjing Agricultural University, 28, 83-87 (in Chinese) Millson S H, Truman A W, King V, Prodromou C, Pearl L H, Piper P W. 2005. A two-hybrid screen of the yeast proteome for Hsp90 interactors uncovers a novel Hsp90 chaperone requirement in the activity of a stress-activated mitogen-activated protein kinase, Slt2p. Mpk1p. Eukaryot Cell, 4, 849-860 Ministry of Health of the People’s Republic China. 2008. The third national survey of cause of death in China. China Cancer, 17, 344-345 (in Chinese) Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D’Andrea G, Dickler M, Moynahan M E, Sugarman S, Ma W, Patil S, Norton L, Hannah A L, Hudis C. 2011. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research, 17, 5132-5139 Morimura T, Ohashi K, Sugimoto C, Onuma M. 1998. Pathogenesis of Marek’s disease(MD) and possible mechanisms of immunity induced by MD vaccine. Journal of Veterinary Medicine Science, 60, 1-8 Ohashi K, Zhou W, O’Connell P H, Schat K A. 1994. Characterization of a Marek’s disease virus BamHI-L-specific cDNA clone obtained from a Marek’s disease lymphoblastoid cell line. Journal of Virology, 68, 1191- 1195. Pick E, Kluger Y, Giltnane J M, Moeder C, Camp R L, Rimm D L, Kluger H M. 2007. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research, 67, 2932-2937 Romanucci M, Marinelli A, Sarli G, Della Salda L. 2006. Heat shock protein expression in canine malignant mammary tumours. BMC Cancer, 6, doi:10.1186/1471-2407-6- 171 Sato S, Fujita N, Tsuruo T 2000. Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 97, 10832-10837. Schulte T W, Blagosklonny M V, Ingui C, Len L. 1995. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association Journal of Biological Chemistry, 270, 24585- 24588. Whitesell L, Sutphin P D, Pulcini E J, Martinez J D, Cook P H. 1998. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Molecular and Cell Biology, 3, 1517-1525. Yahara I. 1992. Structure and function of heat shock proteins. Metabolic Disease, 29, 669-680. Yufu Y, Nishimura J, Nawata H. 1992. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leukemia Research, 16, 597-605. Zhao R, Davey M, Hsu Y C, Kaplanek P, Tong A, Parsons A B, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A, Houry W A. 2005. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell, 120, 715-727 Zhong L, Peng X, Hidalgo G E, Doherty D E, Stromberg A J, Hirschowitz E A. 2003. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detection and Prevention, 27, 285-290 Zhou S P, Cui Z Z. 2003. InfIuence of Marek’s disease virus infections on antibody titers against newcastle disease virus and infectious bursal disease virus vaccines. Chinese Journal of Preventive Veterinary Medicine, 25, 473-475 (in Chinese) Zhu L, Bao E, Zhao R, Hartung J. 2009. Expression of heat shock protein 60 in the tissues of transported piglets. Cell Stress Chaperones, 14, 61-69. |
| No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
